API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. LSE /
  3. 0R1B.LSE

Biogen Inc. (0R1B LSE) stock market data APIs

$202.53 2.66(1.3%) as of September 6, 2024
Price chart is built with Anychart

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc. Financial Data Overview

199.87
202.53
-
202.53
198.63
189.585-268.71
32 541 M
0
9 672 M
4
-0.057
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '0R1B',
Type: 'Common Stock',
Name: 'Biogen Inc.',
Exchange: 'LSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'UK',
CountryISO: 'GB',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: '',
Industry: '',
}

Biogen Inc. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 9 672 M
  • EBITDA 2 729 M
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Biogen Inc. Earnings via APIs

  • Latest Release 2024-08-01
  • EPS/Forecast NaN

Get Biogen Inc. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Biogen Inc. latest news via APIs

Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Amgen (AMGN). Shares have added about 5.8% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up t...

Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder

Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder Wednesday, Biogen Inc. (NASDAQ:BIIB) revealed topline data from the pivotal cohort (P...
Do you have any questions?
support@eodhistoricaldata.com